Smith-Magenis Syndrome Patients Often Display Antibody Deficiency but Not Other Immune Pathologies
- PMID: 28286158
- PMCID: PMC5591748
- DOI: 10.1016/j.jaip.2017.01.028
Smith-Magenis Syndrome Patients Often Display Antibody Deficiency but Not Other Immune Pathologies
Abstract
Background: Smith-Magenis syndrome (SMS) is a complex neurobehavioral disorder associated with recurrent otitis. Most SMS cases result from heterozygous interstitial chromosome 17p11.2 deletions that encompass not only the intellectual disability gene retinoic acid-induced 1 but also other genes associated with immunodeficiency, autoimmunity, and/or malignancy.
Objectives: The goals of this study were to describe the immunological consequence of 17p11.2 deletions by determining the prevalence of immunological diseases in subjects with SMS and by assessing their immune systems via laboratory methods.
Methods: We assessed clinical histories of 76 subjects with SMS with heterozygous 17p11.2 deletions and performed in-depth immunological testing on 25 representative cohort members. Laboratory testing included determination of serum antibody concentrations, vaccine titers, and lymphocyte subset frequencies. Detailed reactivity profiles of SMS serum antibodies were performed using custom-made antigen microarrays.
Results: Of 76 subjects with SMS, 74 reported recurrent infections including otitis (88%), pneumonia (47%), sinusitis (42%), and gastroenteritis (34%). Infections were associated with worsening SMS-related neurobehavioral symptoms. The prevalence of autoimmune and atopic diseases was not increased. Malignancy was not reported. Laboratory evaluation revealed most subjects with SMS to be deficient of isotype-switched memory B cells and many to lack protective antipneumococcal antibodies. SMS antibodies were not more reactive than control antibodies to self-antigens.
Conclusions: Patients with SMS with heterozygous 17p.11.2 deletions display an increased susceptibility to sinopulmonary infections, but not to autoimmune, allergic, or malignant diseases. SMS sera display an antibody reactivity profile favoring neither recognition of pathogen-associated antigens nor self-antigens. Prophylactic strategies to prevent infections may also provide neurobehavioral benefits to selected patients with SMS.
Keywords: Autoantibody; B-cell tolerance; Chromosome 17p11.2 deletion; FLCN; Immune deficiency; Smith-Magenis syndrome; TNFRSF13B; TOM1L2.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
TNF receptor superfamily member 13b (TNFRSF13B) hemizygosity reveals transmembrane activator and CAML interactor haploinsufficiency at later stages of B-cell development.J Allergy Clin Immunol. 2015 Nov;136(5):1315-25. doi: 10.1016/j.jaci.2015.05.012. Epub 2015 Jun 19. J Allergy Clin Immunol. 2015. PMID: 26100089 Free PMC article.
-
Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome.J Allergy Clin Immunol. 2011 Jun;127(6):1579-86. doi: 10.1016/j.jaci.2011.02.046. Epub 2011 Apr 22. J Allergy Clin Immunol. 2011. PMID: 21514638 Free PMC article.
-
Smith-Magenis Syndrome.2001 Oct 22 [updated 2022 Mar 10]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2001 Oct 22 [updated 2022 Mar 10]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301487 Free Books & Documents. Review.
-
Smith-Magenis syndrome: Clinical and behavioral characteristics in a large retrospective cohort.Clin Genet. 2021 Apr;99(4):519-528. doi: 10.1111/cge.13906. Epub 2021 Jan 5. Clin Genet. 2021. PMID: 33368193
-
Immune complex-mediated autoimmunity in a patient With Smith-Magenis syndrome (del 17p11.2).J Clin Rheumatol. 2014 Aug;20(5):291-3. doi: 10.1097/RHU.0000000000000118. J Clin Rheumatol. 2014. PMID: 25036569 Free PMC article. Review.
Cited by
-
Evaluation of immunological abnormalities in patients with rare syndromes.Cent Eur J Immunol. 2022;47(4):299-307. doi: 10.5114/ceji.2022.124080. Epub 2023 Jan 31. Cent Eur J Immunol. 2022. PMID: 36817395 Free PMC article.
-
Smith-Magenis Syndrome-Clinical Review, Biological Background and Related Disorders.Genes (Basel). 2022 Feb 11;13(2):335. doi: 10.3390/genes13020335. Genes (Basel). 2022. PMID: 35205380 Free PMC article. Review.
-
Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.Front Pediatr. 2021 Jun 24;9:688022. doi: 10.3389/fped.2021.688022. eCollection 2021. Front Pediatr. 2021. PMID: 34249818 Free PMC article.
-
Do microdeletions lead to immune deficiency?Cent Eur J Immunol. 2020;45(1):69-72. doi: 10.5114/ceji.2020.94671. Cent Eur J Immunol. 2020. PMID: 32425682 Free PMC article.
References
-
- Smith AC, McGavran L, Robinson J, Waldstein G, Macfarlane J, Zonona J, et al. Interstitial deletion of (17)(p11.2p11.2) in nine patients. Am J Med Genet. 1986 Jul;24(3):393–414. - PubMed
-
- Greenberg F, Lewis RA, Potocki L, Glaze D, Parke J, Killian J, et al. Multidisciplinary clinical study of Smith-Magenis syndrome (deletion 17p11.2) Am J Med Genet. 1996 Mar 29;62(3):247–54. - PubMed
-
- Elsea SH, Girirajan S. Smith–Magenis syndrome. Eur J Hum Genet. 2008 Jan 30;16(4):412–21. - PubMed
-
- Di Cicco M, Padoan R, Felisati G, Dilani D, Moretti E, Guerneri S, et al. Otorhinolaringologic manifestation of Smith-Magenis syndrome. Int J Pediatr Otorhinolaryngol. 2001 Jun 7;59(2):147–50. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
